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Evidence Based Medicine
How should physicians practically approach symptomatic
and asymptomatic carotid stenosis?
Maria Khan, Ayeesha Kamran Kamal
Stroke Service and Vascular Fellowship Program, Aga Khan University Hospital, Stadium Road, Karachi, Pakistan.

The North American Symptomatic Carotid
Endarterectomy Trial-NASCET AND Asymptomatic Carotid
Atherosclerosis Study-ACAS:

Why are these studies important and
noteworthy?
Carotid endarterectomy was first introduced in North
America in 1954 and since then surgeons were performing this
procedure for stroke prevention without much evidence of its
efficacy. In 1988 the NASCET investigators set out to
determine if CE was beneficial in patients with carotid stenosis
and TIA or partial stroke, in other words symptomatic patients.
The same questions applied to patients who had no
prior history of TIA or infarction. Therefore in 1987, the
ACAS investigators designed a study to find out whether the
addition of CE to aspirin plus risk factor modifications will
affect the incidence of TIA or infarctions in patients with
asymptomatic but haemodynamically significant carotid
stenosis in at least one artery.
In the Pakistani perspective, it is important to know
what kind of benefits can be expected from such an invasive
procedure, and what should be the acceptable risk while
undertaking them.

Who were the participants?
NASCET was conducted at 50 centers across USA
and Canada for severe disease and patients with moderate
disease were recruited from 106 centers. The selection of
these centers was based on very stringent criteria. Each center
had a rate of <6% for stroke and death occurring within 30
days of operation for at least 50 consecutive CE performed
within the previous 24 months. Six hundred and sixty two
patients with high-grade stenosis were enrolled between
January 1, 1988 and February 21, 1991. At this point,
randomization of patients with high grade stenosis was
terminated due to evidence of treatment efficacy with CE.
These were patients who had experienced within the past 120
days, one or more TIA or minor stroke, and had ipsilateral
stenosis of more than 30% and less than 100%. Patients who
were 80 years of age or more and who had risk factors for
cardioembolic strokes were excluded. For the moderate
stenosis group, patients were eligible if they had symptoms of
focal cerebral ischaemia ipsilateral to a stenosis of 50-70
696

percent in the ICA, within 180 days, as shown on selective
angiography. Octagenerians were not excluded from this part.
Of the 2226 patients with moderate stenosis, 1118 were
assigned to medical therapy and 1108 got surgical therapy.
There were 858 eligible patients with 50-69% stenosis, and
1368 had <50% stenosis.
ACAS was carried out at 39 centers across the USA.
Candidates were eligible who were between the ages of 40
and 79 years and who had unilateral or bilateral surgically
accessible stenosis of the region of the bifurcation of the
common or internal carotid artery of at least 60%. Those who
had history of TIA or stroke were excluded. During the 6
years of the study, more than 42,000 patients were screened
and 1662 patients were randomized, 825 to the surgical arm
and 834 to the medical arm.

What was the intervention?
In NASCET participating physicians applied the best
available medical therapy to all treatable risk factors in all
patients: Antiplatelet with 1300mg Aspirin per day or a lower
dose if necessitated by side effects and antihypertensive, anti
lipid and anti diabetic therapy for all requiring it. Those in the
surgical arm also underwent CE, the procedure of which was
left to the surgeon's discretion.
In ACAS, All patients received 325 mg of regular or
enteric-coated aspirin daily. Stroke risk factors and their
modification were reviewed with all patients at the time of
randomization and again during subsequent interviews and
telephone follow-ups. This included discussion of diastolic
and systolic hypertension, diabetes mellitus, abnormal lipid
levels, excessive consumption of ethanol, and tobacco use. In
addition, patients randomized to the surgical arm received the
normal evaluation and care of a surgical patient. They were
scheduled to undergo CEA within 2 weeks of randomization.

What was the outcome?
In NASCET, 69% of the patients were males, more
than 90% were whites and 69% had TIA as the entry event.
Hypertension was the predominant risk factor being present
in around 60% whereas diabetes was only there in less than
20% of the patients. The risk of any fatal or non fatal
ipsilateral stroke by 24 months after randomization was 26%
for the medical patients and only 9% for the surgical patients,
J Pak Med Assoc

translating to an absolute risk reduction of 17% and a relative
risk reduction of 64% with surgery. The surgical patients had
an early disadvantage, because of the risk of perioperative
stroke and death which was 1.2% but this was offset by an
absolute risk reduction of 10.6% of any major stroke or death
over the next two years. A secondary analysis showed that
finer divisions of the degree of high-grade stenosis correlated
with the degrees of risk reduction after surgery.
For the primary analysis of any fatal or nonfatal
ipsilateral stroke, in the moderate stenosis group of NASCET,
the five-year failure rate for patients with 50 to 69 percent
stenosis was 22.2 percent for medically treated patients and
15.7 percent for surgically treated patients (P=0.045). This
meant an absolute risk reduction of 6.5% and a relative risk
reduction of 29%. Also 15 patients would need to be treated
by endarterectomy to prevent one ipsilateral stroke at five
years. For patients with stenosis of less than 50 percent, the
corresponding five-year failure rates were 18.7 percent for
medically treated patients and 14.9 percent for surgically
treated patients (P=0.16).
In ACAS as well, more than 80% of the patients were
above 60, 66% were males, and more than 90% were white.
Hypertension was again the commonest risk factor, with DM
present in only 20% of the patients. For the surgical group,
the risk in the perioperative period was 2.3% (95% CI, 1.28%
to 3.32%), whereas for the medical group it was 0.4% (95%
CI, 0.0% to 0.8%). All patients randomized to the surgical
group were required to have arteriography. Of the 414
patients who underwent arteriography prior to CEA, five
experienced a cerebral infarction, for an artériographic
complication rate of 1.2%. The study achieved its
significance after a median of 2.7 years of follow-up. The
estimated 5-year risk of ipsilateral stroke and any
perioperative stroke or death was 11.0% for the medical
group and 5.1% for the surgical group. The reduction in 5year ipsilateral stroke risk in the surgical group was 53% of
the estimated 5-year risk in the medical group (p=0.004).
Although not statistically significant, men had a better
outcome with surgery then women with fewer operative
complications.

What were the conclusions?
NASCET and ACAS were two large trials carried out
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in patients with carotid stenosis. The NASCET shows that
symptomatic patients with carotid stenosis of >70% derive
substantial benefit from CE that persists for more than 5
years. Those with stenosis between 50-70% benefit less, and
those with stenosis <50% derive no advantage from surgery.
ACAS evaluated asymptomatic patients and showed
that those with greater than 60% stenosis benefit from CE,
with evidence of benefit being more robust in men than in
women.

How does this impact our clinical practice?
Before
NASCET
and
ACAS,
carotid
endarterectomies were being performed without much
evidence of their long term benefits. These two trials not just
provided this evidence but also laid down standards for
perioperative care in CE.
In Pakistan, carotid disease is not such a major risk
factor. But in those who have the disease, surgery is definitely
advisable for symptomatic individuals with greater than 70%
stenosis, and perhaps also in those with moderate stenosis.
For asymptomatic individuals again, it can be considered in
men with greater than 60% stenosis. However, what must be
kept in mind is that the benefit will only be realized at a center
offering an angiography complication rate in the range of
1.2% and a carotid endarterectomy complication rate in the
range of 2.1%. With higher rates of complications, the benefit
will diminish. Also NASCET showed that if they have no
recurring symptoms, patients have little to gain from
endarterectomy after two to three years of the initial event.
We should offer this procedure to patients in centers
where the perioperative complications are regularly audited.
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